Compare Ginkgo Bioworks Holdings Inc (DNA) vs iShares MSCI Indonesia ETF (EIDO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs iShares MSCI Indonesia ETF — how do they compare? Ginkgo Bioworks Holdings Inc trades at $11.78 (market cap $763.64M), while iShares MSCI Indonesia ETF trades at $11.8 (market cap $409.22M). The key difference: Ginkgo Bioworks Holdings Inc is the larger of the two by market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and iShares MSCI Indonesia ETF for 75 Days on average.
| DNA | EIDO | |
|---|---|---|
Market Cap | $763.64M | $409.22M |
Volume | 3,204,177 | 879,527 |
Sector | Health | — |
52-Week High | $15.83 | $19.22 |
52-Week Low | $5.48 | $10.80 |
Typical Hold Time | 7 Days | 75 Days |
Enterprise Value | $865.59M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% today, reflecting ongoing volatility. The stock shows a bullish technical signal with strong moving average support, but fundamentals reveal significant challenges: revenue declined to $170.16M in 2025 with a net loss of $312.76M, and negative cash flow persists. Recent news includes a partnership with TuneLab for AI-driven drug discovery and a $17.5M ARPA-H subcontract for RNA medicine manufacturing, indicating strategic growth initiatives amid financial headwinds.
The outlook remains high-risk due to persistent losses and cash burn, though analyst sentiment is split evenly between buy, hold, and sell. Upside potential hinges on successful commercialization of its platform and cost management, while downside risks include execution missteps and prolonged profitability challenges. Investors should weigh the company's innovative partnerships against its weak financial metrics.
EIDO (iShares MSCI Indonesia ETF) trades at $11.86, down 0.59% with bearish technical signals from moving averages. The ETF faces headwinds as foreign capital rotates away from Asian markets, with recent news highlighting Indonesia's failure to benefit from commodity gains despite attractive valuations. Trading volume declined 21% below average, indicating reduced investor interest.
The outlook remains cautious with technical weakness outweighing valuation appeal. Key risks include heavy financial sector exposure (44%) and limited EPS growth potential. Seasonal patterns historically favor July-August performance, but current market dynamics suggest continued pressure on Indonesian equities amid regional capital outflows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →
